Risvutatug rezetecan

Phase 3Small molecule

Risvutatug rezetecan is one of 52 small molecule programs targeting Gastrointestinal Neoplasms. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastrointestinal NeoplasmsRecruiting

Neoplasms, ProstateNot yet recruiting

GliomaRecruiting

Gastrointestinal NeoplasmsPreclinical

Recruiting

Neoplasms, ProstatePhase 3

Not yet recruiting

GliomaPhase 1

Recruiting

Competition

Competitive Landscape

103 competitors in Glioma

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 3

23 2

Paraplatin

AAvyxa

Phase 3

13 3

Voranigo

SServier

Phase 3

5 4

Ojemda

Day One Biopharmaceuticals

Phase 3

3 5

Opdivo

Bristol-Myers Squibb

Phase 2

13 6

Camptosar

Pfizer

Phase 2

5 7

Keytruda

Merck & Co.

Phase 2

5 8

Verzenio

Eli Lilly

Phase 2

3 9

Lynparza

AstraZeneca

Phase 2

3 10

Dostarlimab

Incyte

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

PreclinicalRecruiting

Gastrointestinal Neoplasms

NCT06885034

Q3 2029

Phase 1Recruiting

Glioma

NCT07268053

Q4 2029

Phase 3Not yet recruiting

Neoplasms, Prostate

NCT07802704

PreclinicalNot yet recruiting

Neoplasms, Lung

NCT07602855

Clinical

Trials by Indication[1]

Glioma1 trial

A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases

Recruiting·NNader Sanai·Phase 1·NCT07268053·15 enrolled

Neoplasms, Lung1 trial

A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors

Not yet recruiting· GSK logo

GSK·Preclinical·NCT07602855·184 enrolled

Neoplasms, Prostate1 trial

A Phase 3 Randomized Study to Evaluate the Safety and Efficacy of Risvutatug Rezetecan, a B7-H3 Antibody Drug Conjugate (ADC) in Participants With Metastatic Castration-resistant Prostate Cancer (EMBOLD Prostate-302)

Not yet recruiting· GSK logo

GSK·Phase 3·NCT07802704·684 enrolled

Gastrointestinal Neoplasms1 trial

A Phase1 b/2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of GSK5764227 Alone and in Combination in Participants With Previously Treated Advanced Unresectable or Metastatic Gastrointestinal Solid Tumors

Recruiting· GSK logo

GSK·Preclinical·NCT06885034·451 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Risvutatug rezetecan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Risvutatug rezetecan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Risvutatug rezetecan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nader Sanai company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNader Sanai

Risvutatug rezetecan

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Q3 2029

Q4 2029

Trials by Indication[1]

Glioma1 trial

Neoplasms, Lung1 trial

Neoplasms, Prostate1 trial

Gastrointestinal Neoplasms1 trial

References

Drug Info

Quick Facts

Related News